Abstract
In order to evaluate the relationship between plasma nortriptyline concentration and anticholinergic effect, a single blind cross-over study of nortriptyline was performed. Seventeen healthy male volunteers were given single doses of nortriptyline (25, 50, and 75 mg) and placebo in a cross-over manner. Plasma nortriptyline concentration was measured by high performance liquid chromatography and spontaneous salivation flow was measured. Peak plasma levels of nortriptyline were attained at about 5 hours after drug administration. The corresponding area under the plasma concentration time curve (AUC) from zero-time to 12 hours after the respective dose of 25 mg, 50 mg and 75 mg nortriptyline were 87.1 ± 32.8 ng ml-1·h (n = 7), 231.2 ± 61.3 ng ml-1·h (n = 5) and 293.0 ± 83.9 ng ml-1·h (n = 5), respectively. Saliva flow significantly decreased in all dose groups when compared with placebo. The percentage inhibitions of salivation at each indicated dose were 24.2 ± 12.1% (25 mg), 38.3 ± 13.2% (50 mg) and 51.9 ± 10.3% (75 mg). The inhibition of salivation showed highest correlation with log cumulative plasma levels of nortriptyline. The twelve hour plasma AUC which showed 50% inhibition of salivation was 338.7 ng ml-1·h.
| Original language | English |
|---|---|
| Pages (from-to) | 249-254 |
| Number of pages | 6 |
| Journal | Asia Pacific Journal of Pharmacology |
| Volume | 6 |
| Issue number | 3 |
| Publication status | Published - 1991 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
Cite this
}
Assessment of the relationship between plasma nortriptyline concentration and inhibition of salivation : Single-dose study. / Jang, I. J.; Shin, J. G.; Shin, S. G.; Kim, Jae-Jin; Woo, J. I.; Lee, Y. S.; Park, C. W.
In: Asia Pacific Journal of Pharmacology, Vol. 6, No. 3, 01.01.1991, p. 249-254.Research output: Contribution to journal › Article
TY - JOUR
T1 - Assessment of the relationship between plasma nortriptyline concentration and inhibition of salivation
T2 - Single-dose study
AU - Jang, I. J.
AU - Shin, J. G.
AU - Shin, S. G.
AU - Kim, Jae-Jin
AU - Woo, J. I.
AU - Lee, Y. S.
AU - Park, C. W.
PY - 1991/1/1
Y1 - 1991/1/1
N2 - In order to evaluate the relationship between plasma nortriptyline concentration and anticholinergic effect, a single blind cross-over study of nortriptyline was performed. Seventeen healthy male volunteers were given single doses of nortriptyline (25, 50, and 75 mg) and placebo in a cross-over manner. Plasma nortriptyline concentration was measured by high performance liquid chromatography and spontaneous salivation flow was measured. Peak plasma levels of nortriptyline were attained at about 5 hours after drug administration. The corresponding area under the plasma concentration time curve (AUC) from zero-time to 12 hours after the respective dose of 25 mg, 50 mg and 75 mg nortriptyline were 87.1 ± 32.8 ng ml-1·h (n = 7), 231.2 ± 61.3 ng ml-1·h (n = 5) and 293.0 ± 83.9 ng ml-1·h (n = 5), respectively. Saliva flow significantly decreased in all dose groups when compared with placebo. The percentage inhibitions of salivation at each indicated dose were 24.2 ± 12.1% (25 mg), 38.3 ± 13.2% (50 mg) and 51.9 ± 10.3% (75 mg). The inhibition of salivation showed highest correlation with log cumulative plasma levels of nortriptyline. The twelve hour plasma AUC which showed 50% inhibition of salivation was 338.7 ng ml-1·h.
AB - In order to evaluate the relationship between plasma nortriptyline concentration and anticholinergic effect, a single blind cross-over study of nortriptyline was performed. Seventeen healthy male volunteers were given single doses of nortriptyline (25, 50, and 75 mg) and placebo in a cross-over manner. Plasma nortriptyline concentration was measured by high performance liquid chromatography and spontaneous salivation flow was measured. Peak plasma levels of nortriptyline were attained at about 5 hours after drug administration. The corresponding area under the plasma concentration time curve (AUC) from zero-time to 12 hours after the respective dose of 25 mg, 50 mg and 75 mg nortriptyline were 87.1 ± 32.8 ng ml-1·h (n = 7), 231.2 ± 61.3 ng ml-1·h (n = 5) and 293.0 ± 83.9 ng ml-1·h (n = 5), respectively. Saliva flow significantly decreased in all dose groups when compared with placebo. The percentage inhibitions of salivation at each indicated dose were 24.2 ± 12.1% (25 mg), 38.3 ± 13.2% (50 mg) and 51.9 ± 10.3% (75 mg). The inhibition of salivation showed highest correlation with log cumulative plasma levels of nortriptyline. The twelve hour plasma AUC which showed 50% inhibition of salivation was 338.7 ng ml-1·h.
UR - http://www.scopus.com/inward/record.url?scp=0026051597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026051597&partnerID=8YFLogxK
M3 - Article
VL - 6
SP - 249
EP - 254
JO - Asia Pacific Journal of Pharmacology
JF - Asia Pacific Journal of Pharmacology
SN - 0217-9687
IS - 3
ER -